Marksans Pharma Ltd.
Snapshot View

86.10 -0.30 ▼-0.4%

26 July 2021, 09:38:00 A.M.
Volume: 13,209

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.marksanspharma.com
Financial Indicators
Market Cap 3,536.47 Cr.
Earnings per share (EPS) 5.83 Trailing Twelve Months Ending 2021-03
Price-Earning Ratio (PE) 14.83 Trailing Twelve Months Ending 2021-03
Industry PE 35.17 Trailing Twelve Months Ending 2021-03
Book Value / Share 21.66 Trailing Twelve Months Ending 2021-03
Price to Book Value 3.99 Calculated using Price: 86.40
Dividend Yield 0.29 Period Ending 2020-03
No. of Shares Subscribed 40.93 Cr. 409,313,698 Shares
FaceValue 1
Company Profile

Marksans Pharma, incorporated in 1992, was a wholly-owned subsidiary of Glenmark Pharmaceuticals. It became a separate entity in March 2003 and the name was changed to Marksans Pharma in 2005.

Currently the company has presence in Active Pharmaceuticals Ingredients (APIs), formulations and biopharmaceuticals. It is also actively engaged in research and development and offers contract research and manufacturing services (CRAMS) to global pharmaceutical companies.

The company, engaged in production of prescription drugs, caters in areas like oncology, gastroenterology, antidiabetic, cardiovascular, pain management, gynaecology and others.

The company's plants have been built as per USFDA guidelines and have received approval from various health authorities namely TGA (Australia), MHRA (United Kingdom) ANVISA (Brazil) apart from WHO GMP certificate.

Marksans Pharma  acquired Relonchem, a leading UK-based generic pharmaceutical company. This acquisition gave company an immediate sales and marketing front-end access to the highly regulated and lucrative generic medicines market in UK and Europe.

Marksans Pharma exports its products to markets in Europe, Latin America, Africa and Oceania.

In 2010 Company entered into a Business Transfer Agreement with Kores (India) Limited

Business area

Research and Development- The company’s R&D centre is situated in Goa and is engaged in new drug discovery chemistry, pharmacokinetics, pharmacology/ molecular biology, toxicology, and related skills and support areas.

Formulation- This division is engaged in manufacturing of tablets, non-sterile liquids, ointments and powder products. The company owns one of the biggest manufacturing facility for soft gelatin in Asia. The company’s manufacturing plants are located at Goa and UK.

APIs- Marksans' two APIs manufacturing units are located in Pune. The present manufacturing capacity of 1140 TPA that comprises of 600 TPA Quinolones, 360 TPA Ranitidine, and 180 others.

CRAMS- The company has alliances with the top 8 MNC generic companies for contract manufacturing of 30 generic products for the European markets. It has entered into licensing agreements with numerous companies for development and supply of products for 7-10 years.

Milestones

  • 2016 -Marksans Pharma gets USFDA nod for Paricalcitol capsules
    -Marksans Pharma gets USFDA nod for diabetes treatment drug
    -Marksans Pharma bags USFDA approval for Loratadine
  • 2015 -Marksans Pharma gains on acquiring Time-Cap Laboratories
  • 2009 - Marksans Pharma establlished itself as a global player
  • 2008 - Acquired Bells, Sons & Co. (Druggists) Ltd.         
  • Acquired Relonchem Limited
  • 2005 - Acquired Nova Pharmaceuticals Australasia Pty Ltd.
  • 2003 - Spun-off into a separate entity - Glenmark Laboratories Ltd.         
  •  Changed its name to 'Marksans Pharma Ltd'
  • 2001  - Marksans was incorporated as a wholly owned subsidiary of Glenmark Pharmaceuticals Ltd.

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
-0.35%
1 Week
-2.66%
1 Month
-1.15%
3 Month
+26.06%
6 Month
+59.00%
1 Year
+138.17%
2 Year
+451.92%
5 Year
+82.80%
9 years 2012-03 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03
Return on Equity (%) 73.02 45.15 20.45 2.59 7.92 15.88 20.49
Return on Capital Employed (%) -180.20 44.72 38.30 44.64 23.16 3.99 10.60 18.51 25.57
Return on Assets (%) -40.16 12.42 16.52 19.21 11.86 1.54 4.83 10.49 14.22

Balance Sheet View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Shh. Funds -168 86 142 380 454 433 471 542 636
Non Curr. Liab. 28 10 22 1 -2 16 16 17 27
Curr. Liab. 519 297 319 286 259 296 235 233 220
Minority Int. 6 7 7 8 8 6 10 10 13
Equity & Liab. 385 401 490 676 720 752 731 802 896
Non Curr. Assets 169 157 147 167 280 268 280 271 306
Curr. Assets 216 244 343 509 440 484 451 531 590
Misc. Exp. not W/O
Total Assets 385 401 490 676 720 752 731 802 896

Profit Loss View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Net Sales 356 438 630 797 893 767 913 1,000 1,134
Other Income 2 4 7 12 13 19 8 5 0
Total Income 358 443 637 809 906 786 921 1,005 1,135
Total Expenditure -455 -369 -516 -621 -761 -734 -834 -868 -942
PBIDT -98 74 121 188 145 52 87 137 193
Interest -54 -15 -19 -16 -10 -7 -10 -10 -9
Depreciation -24 -16 -16 -16 -28 -30 -27 -23 -27
Taxation -1 5 -13 -44 -24 -4 -14 -24 -36
Exceptional Items
PAT -176 49 74 112 83 11 36 80 121

Cash Flow View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Cash Fr. Operatn. -62 39 65 155 31 14 50 27 210
Cash Fr. Inv. -3 -5 -4 -33 -123 -21 -39 -13 -60
Cash Fr. Finan. 57 -40 -29 17 -58 -3 3 -21 -90
Net Change -9 -7 31 138 -150 -10 15 -7 60
Cash & Cash Eqvt 22 16 47 185 35 25 40 33 93

Shareholding Pattern View Details

9 Qtrs 2019-06 (%) 2019-09 (%) 2019-12 (%) 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%)
Promoter 48.25 48.25 48.25 48.25 48.25 48.25 48.25 48.25 48.25
Public 51.75 51.75 51.75 51.75 51.75 51.75 51.75 51.75 51.75
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Sat, 24 Jul 2021
Announcement under Regulation 30 (LODR)-Code of Conduct under SEBI (PIT) Regulations 2015
Pursuant to SEBI Circular No. SEBI/HO/ISD/CIR/P/2020/135 dated July 23 2020 enclosed herewith kindly find reporting of violations related to Code of Conduct under SEBI (PIT) Regulations 2015 by two Designated Persons of the Company in the prescribed formats.
Fri, 23 Jul 2021
Announcement under Regulation 30 (LODR)-Allotment
The Board of Directors at its meeting held today i.e. 23rd July 2021 has created issued and allotted 5 03 24 324 convertible warrants on preferential basis.
Mon, 19 Jul 2021
Shareholding for the Period Ended June 30 2021
Marksans Pharma Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30 2021. For more details kindly Click here

Technical Scans View Details

Fri, 23 Jul 2021
Close Within 2 Year High Zone Close Within 2 Year High Zone
Close Within 5 Year High Zone Close Within 5 Year High Zone
Both SRS And ARS Above Zero Both SRS And ARS Above Zero
Close Crossing 20 EMA From Above Close Crossing 20 EMA From Above
Stochastic Entering Oversold Zone From Above Stochastic Entering Oversold Zone From Above

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 166,513.85 700.75 +1.0%
Divi's Laboratories Ltd. 128,088.59 4,888.80 +1.3%
Dr. Reddy's Laboratories Ltd. 90,175.51 5,433.95 +0.2%
Cipla Ltd. 76,510.04 956.45 +0.9%
Cadila Healthcare Ltd. 62,965.29 611.20 -0.6%
Aurobindo Pharma Ltd. 56,484.48 965.15 +0.2%
Apollo Hospitals Enterprise Ltd. 56,291.69 3,996.05 +2.0%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 57.34 700.75 +1.0%
Divi's Laboratories Ltd. Consolidated 2021-03 64.55 4,888.80 +1.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 46.21 5,433.95 +0.2%
Cipla Ltd. Consolidated 2021-03 31.81 956.45 +0.9%
Cadila Healthcare Ltd. Consolidated 2021-03 29.51 611.20 -0.6%
Aurobindo Pharma Ltd. Consolidated 2021-03 10.59 965.15 +0.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 374.38 3,996.05 +2.0%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 3.58 700.75 +1.0%
Divi's Laboratories Ltd. Consolidated 2021-03 13.78 4,888.80 +1.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 5.15 5,433.95 +0.2%
Cipla Ltd. Consolidated 2021-03 4.17 956.45 +0.9%
Cadila Healthcare Ltd. Consolidated 2021-03 4.85 611.20 -0.6%
Aurobindo Pharma Ltd. Consolidated 2021-03 2.58 965.15 +0.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 12.25 3,996.05 +2.0%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 0.18 700.75 +1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 0.00 4,888.80 +1.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 5,433.95 +0.2%
Cipla Ltd. Consolidated 2020-03 0.18 956.45 +0.9%
Cadila Healthcare Ltd. Consolidated 2021-03 0.35 611.20 -0.6%
Aurobindo Pharma Ltd. Consolidated 2020-03 0.33 965.15 +0.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 1.08 3,996.05 +2.0%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 9.66 700.75 +1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 19.30 4,888.80 +1.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 5,433.95 +0.2%
Cipla Ltd. Consolidated 2020-03 10.09 956.45 +0.9%
Cadila Healthcare Ltd. Consolidated 2021-03 18.30 611.20 -0.6%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.53 965.15 +0.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 13.08 3,996.05 +2.0%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 10.07 700.75 +1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 25.36 4,888.80 +1.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 15.24 5,433.95 +0.2%
Cipla Ltd. Consolidated 2020-03 12.53 956.45 +0.9%
Cadila Healthcare Ltd. Consolidated 2021-03 13.65 611.20 -0.6%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.80 965.15 +0.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 17.13 3,996.05 +2.0%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 32,837.50 700.75 +1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 5,394.42 4,888.80 +1.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 5,433.95 +0.2%
Cipla Ltd. Consolidated 2020-03 17,131.99 956.45 +0.9%
Cadila Healthcare Ltd. Consolidated 2021-03 15,102.20 611.20 -0.6%
Aurobindo Pharma Ltd. Consolidated 2020-03 23,098.51 965.15 +0.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 11,246.80 3,996.05 +2.0%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 4,186.79 700.75 +1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 1,376.54 4,888.80 +1.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 5,433.95 +0.2%
Cipla Ltd. Consolidated 2020-03 1,546.98 956.45 +0.9%
Cadila Healthcare Ltd. Consolidated 2021-03 2,137.60 611.20 -0.6%
Aurobindo Pharma Ltd. Consolidated 2020-03 2,844.69 965.15 +0.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 434.90 3,996.05 +2.0%